XBiotech Inc
XBIT2.835USD
-0.015-0.53%
Market hours （ET）Quotes delayed by 15 min
86.43MMarket Cap
LossP/E TTM
More Details of XBiotech Inc Company
XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies for treating a variety of diseases, such as inflammatory conditions like rheumatology, infectious disease, cardiovascular disease and cancer. The Company's True Human monoclonal antibodies are derived from human donors that mount a natural human immune response. The Company is focused on therapies that block a potent substance, known as interleukin-1 alpha (IL-1a), that mediates a number of pathophysiological processes including tissue breakdown (i.e. synovium, cartilage, bone), paraneoplastic angiogenesis and tumor stroma remodeling, formation of blood clots, malaise, muscle wasting and general inflammation. It has various candidate products including Natrunix. It has a clinical-stage therapeutic for methicillin resistant Staphylococcus aureus (MRSA), and several pre-clinical-stage therapeutics, including an oral delivery antibody therapeutic for colon infection by C. difficile.
Company Info
Ticker SymbolXBIT
Company nameXBiotech Inc
IPO dateApr 15, 2015
CEOMr. John Simard
Number of employees92
Security typeOrdinary Share
Fiscal year-endApr 15
Address5217 Winnebago Lane
CityAUSTIN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code78744
Phone15123862900
Websitehttps://www.xbiotech.com/
Ticker SymbolXBIT
IPO dateApr 15, 2015
CEOMr. John Simard
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. John Simard
Mr. John Simard
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
3.82M
--
Mr. Jan-Paul Waldin, Esq.
Mr. Jan-Paul Waldin, Esq.
Lead Independent Director
Lead Independent Director
200.24K
--
Mr. Craig Rademaker
Mr. Craig Rademaker
Independent Director
Independent Director
170.99K
--
Ms. Angela Hu
Ms. Angela Hu
Director of Finance
Director of Finance
25.50K
--
Dr. Tak Mak, Ph.D.
Dr. Tak Mak, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Libby, M.D.
Dr. Peter Libby, M.D.
Independent Director
Independent Director
--
--
Dr. Sushma Shivaswamy, Ph.D.
Dr. Sushma Shivaswamy, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Prof. Dr. Thomas Kuendig
Prof. Dr. Thomas Kuendig
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. John Simard
Mr. John Simard
Chairman of the Board, President, Chief Executive Officer, Founder
Chairman of the Board, President, Chief Executive Officer, Founder
3.82M
--
Mr. Jan-Paul Waldin, Esq.
Mr. Jan-Paul Waldin, Esq.
Lead Independent Director
Lead Independent Director
200.24K
--
Mr. Craig Rademaker
Mr. Craig Rademaker
Independent Director
Independent Director
170.99K
--
Ms. Angela Hu
Ms. Angela Hu
Director of Finance
Director of Finance
25.50K
--
Dr. Tak Mak, Ph.D.
Dr. Tak Mak, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Libby, M.D.
Dr. Peter Libby, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
No Data
By RegionUSD
Name
Revenue
Proportion
United States
0.00
0.00%
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 9
Updated: Wed, Jul 9
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gut (Thomas)
12.84%
Simard (John)
12.54%
McKenzie (Thorpe W)
8.87%
BlackRock Institutional Trust Company, N.A.
3.76%
The Vanguard Group, Inc.
3.49%
Other
58.51%
Shareholders
Shareholders
Proportion
Gut (Thomas)
12.84%
Simard (John)
12.54%
McKenzie (Thorpe W)
8.87%
BlackRock Institutional Trust Company, N.A.
3.76%
The Vanguard Group, Inc.
3.49%
Other
58.51%
Shareholder Types
Shareholders
Proportion
Individual Investor
36.61%
Investment Advisor
9.46%
Investment Advisor/Hedge Fund
4.10%
Research Firm
0.66%
Hedge Fund
0.38%
Bank and Trust
0.28%
Pension Fund
0.01%
Other
48.50%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
134
15.23M
49.96%
-1.14M
2025Q1
143
15.26M
50.05%
-1.19M
2024Q4
140
15.53M
50.95%
-1.01M
2024Q3
137
15.65M
51.38%
-708.95K
2024Q2
133
15.28M
50.16%
-81.14K
2024Q1
158
14.75M
48.44%
-771.65K
2023Q4
162
15.59M
51.20%
-1.96M
2023Q3
178
15.26M
50.15%
-2.83M
2023Q2
182
15.29M
50.24%
-1.85M
2023Q1
192
14.37M
47.22%
-3.11M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gut (Thomas)
3.91M
12.84%
--
--
Mar 18, 2025
Simard (John)
3.82M
12.54%
--
--
Mar 18, 2025
McKenzie (Thorpe W)
2.70M
8.87%
-16.25K
-0.60%
Mar 18, 2025
BlackRock Institutional Trust Company, N.A.
1.15M
3.76%
-15.32K
-1.32%
Mar 31, 2025
The Vanguard Group, Inc.
1.06M
3.49%
-1.83K
-0.17%
Mar 31, 2025
Geode Capital Management, L.L.C.
461.23K
1.51%
+6.70K
+1.47%
Mar 31, 2025
State Street Global Advisors (US)
229.69K
0.75%
--
--
Mar 31, 2025
Waldin (Jan-Paul)
200.24K
0.66%
--
--
Mar 18, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 ETF
0%
Avantis US Small Cap Equity ETF
0%
Global X Russell 2000 ETF
0%
Fidelity Enhanced Small Cap ETF
0%
ProShares Hedge Replication ETF
0%
Avantis US Small Cap Value ETF
0%
ProShares UltraPro Russell2000
0%
iShares Russell 2000 Value ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
Proportion0.01%
iShares Russell 2000 ETF
Proportion0%
Avantis US Small Cap Equity ETF
Proportion0%
Global X Russell 2000 ETF
Proportion0%
Fidelity Enhanced Small Cap ETF
Proportion0%
ProShares Hedge Replication ETF
Proportion0%
Avantis US Small Cap Value ETF
Proportion0%
ProShares UltraPro Russell2000
Proportion0%
iShares Russell 2000 Value ETF
Proportion0%
Proshares Ultra Russell 2000
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
